123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia

Nuklearmedizin. 1994 Oct;33(5):194-9.

Abstract

In 58 patients with Parkinsonism or dystonia striatal dopamine D2 receptors were investigated using 123I-iodobenzamide (123I-IBZM) single-photon emission computed tomography (SPECT). The influence of SPECT reconstruction methodology on semiquantification and the clinical value of 123I-IBZM SPECT were evaluated. Delineation of the striatal uptake and striatum/frontal cortex (ST/FC) ratios were improved by the use of compensation procedures for scatter and attenuation as well as the choice of an adequate filter. Satisfactory results were achieved using a Metz prefilter with a comparatively high order number (i.e. high cut-off and low suppression of higher frequencies via roll-off). Regarding clinical diagnoses it was not possible to differentiate between advanced idiopathic Parkinson's disease (IP) and Parkinsonism of other aetiology (OP) on the basis of 123I-IBZM SPECT. But patients with IP and favourable response to L-Dopa showed significantly higher ST/FC ratios than those with fluctuating response. In patients with dystonia ST/FC ratios were significantly higher compared to patients with IP or OP.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides / metabolism
  • Benzamides / therapeutic use*
  • Corpus Striatum / diagnostic imaging*
  • Corpus Striatum / metabolism
  • Dopamine Antagonists
  • Dystonia / diagnostic imaging*
  • Dystonia / metabolism
  • Frontal Lobe / diagnostic imaging*
  • Frontal Lobe / metabolism
  • Humans
  • Iodine Radioisotopes
  • Middle Aged
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / metabolism
  • Pyrrolidines / metabolism
  • Pyrrolidines / therapeutic use*
  • Receptors, Dopamine D2 / analysis
  • Receptors, Dopamine D2 / metabolism
  • Tomography, Emission-Computed, Single-Photon / methods*

Substances

  • Benzamides
  • Dopamine Antagonists
  • Iodine Radioisotopes
  • Pyrrolidines
  • Receptors, Dopamine D2
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide